Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
Saved in:
| Title: | Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. |
|---|---|
| Authors: | Menni, Cristina (AUTHOR), Valdes, Ana M (AUTHOR), Polidori, Lorenzo (AUTHOR), Antonelli, Michela (AUTHOR), Penamakuri, Satya (AUTHOR), Nogal, Ana (AUTHOR), Louca, Panayiotis (AUTHOR), May, Anna (AUTHOR), Figueiredo, Jane C (AUTHOR), Hu, Christina (AUTHOR), Molteni, Erika (AUTHOR), Canas, Liane (AUTHOR), Österdahl, Marc F (AUTHOR), Modat, Marc (AUTHOR), Sudre, Carole H (AUTHOR), Fox, Ben (AUTHOR), Hammers, Alexander (AUTHOR), Wolf, Jonathan (AUTHOR), Capdevila, Joan (AUTHOR), Chan, Andrew T (AUTHOR) |
| Source: | Lancet. 4/23/2022, Vol. 399 Issue 10335, p1618-1624. 7p. |
| Abstract: | The SARS-CoV-2 variant of concern, omicron, appears to be less severe than delta. We aim to quantify the differences in symptom prevalence, risk of hospital admission, and symptom duration among the vaccinated population. In this prospective longitudinal observational study, we collected data from participants who were self-reporting test results and symptoms in the ZOE COVID app (previously known as the COVID Symptoms Study App). Eligible participants were aged 16–99 years, based in the UK, with a body-mass index between 15 and 55 kg/m2, had received at least two doses of any SARS-CoV-2 vaccine, were symptomatic, and logged a positive symptomatic PCR or lateral flow result for SARS-CoV-2 during the study period. The primary outcome was the likelihood of developing a given symptom (of the 32 monitored in the app) or hospital admission within 7 days before or after the positive test in participants infected during omicron prevalence compared with those infected during delta prevalence. Between June 1, 2021, and Jan 17, 2022, we identified 63 002 participants who tested positive for SARS-CoV-2 and reported symptoms in the ZOE app. These patients were matched 1:1 for age, sex, and vaccination dose, across two periods (June 1 to Nov 27, 2021, delta prevalent at >70%; n=4990, and Dec 20, 2021, to Jan 17, 2022, omicron prevalent at >70%; n=4990). Loss of smell was less common in participants infected during omicron prevalence than during delta prevalence (16·7% vs 52·7%, odds ratio [OR] 0·17; 95% CI 0·16–0·19, p<0·001). Sore throat was more common during omicron prevalence than during delta prevalence (70·5% vs 60·8%, 1·55; 1·43–1·69, p<0·001). There was a lower rate of hospital admission during omicron prevalence than during delta prevalence (1·9% vs 2·6%, OR 0·75; 95% CI 0·57–0·98, p=0·03). The prevalence of symptoms that characterise an omicron infection differs from those of the delta SARS-CoV-2 variant, apparently with less involvement of the lower respiratory tract and reduced probability of hospital admission. Our data indicate a shorter period of illness and potentially of infectiousness which should impact work–health policies and public health advice. Wellcome Trust, ZOE, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, and Medical Research Council [ABSTRACT FROM AUTHOR] |
| Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 157139852 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Menni%2C+Cristina%22">Menni, Cristina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Valdes%2C+Ana+M%22">Valdes, Ana M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Polidori%2C+Lorenzo%22">Polidori, Lorenzo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Antonelli%2C+Michela%22">Antonelli, Michela</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Penamakuri%2C+Satya%22">Penamakuri, Satya</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nogal%2C+Ana%22">Nogal, Ana</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Louca%2C+Panayiotis%22">Louca, Panayiotis</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22May%2C+Anna%22">May, Anna</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Figueiredo%2C+Jane+C%22">Figueiredo, Jane C</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hu%2C+Christina%22">Hu, Christina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Molteni%2C+Erika%22">Molteni, Erika</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Canas%2C+Liane%22">Canas, Liane</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Österdahl%2C+Marc+F%22">Österdahl, Marc F</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Modat%2C+Marc%22">Modat, Marc</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sudre%2C+Carole+H%22">Sudre, Carole H</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fox%2C+Ben%22">Fox, Ben</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hammers%2C+Alexander%22">Hammers, Alexander</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wolf%2C+Jonathan%22">Wolf, Jonathan</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Capdevila%2C+Joan%22">Capdevila, Joan</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chan%2C+Andrew+T%22">Chan, Andrew T</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 4/23/2022, Vol. 399 Issue 10335, p1618-1624. 7p. – Name: Abstract Label: Abstract Group: Ab Data: The SARS-CoV-2 variant of concern, omicron, appears to be less severe than delta. We aim to quantify the differences in symptom prevalence, risk of hospital admission, and symptom duration among the vaccinated population. In this prospective longitudinal observational study, we collected data from participants who were self-reporting test results and symptoms in the ZOE COVID app (previously known as the COVID Symptoms Study App). Eligible participants were aged 16–99 years, based in the UK, with a body-mass index between 15 and 55 kg/m2, had received at least two doses of any SARS-CoV-2 vaccine, were symptomatic, and logged a positive symptomatic PCR or lateral flow result for SARS-CoV-2 during the study period. The primary outcome was the likelihood of developing a given symptom (of the 32 monitored in the app) or hospital admission within 7 days before or after the positive test in participants infected during omicron prevalence compared with those infected during delta prevalence. Between June 1, 2021, and Jan 17, 2022, we identified 63 002 participants who tested positive for SARS-CoV-2 and reported symptoms in the ZOE app. These patients were matched 1:1 for age, sex, and vaccination dose, across two periods (June 1 to Nov 27, 2021, delta prevalent at >70%; n=4990, and Dec 20, 2021, to Jan 17, 2022, omicron prevalent at >70%; n=4990). Loss of smell was less common in participants infected during omicron prevalence than during delta prevalence (16·7% vs 52·7%, odds ratio [OR] 0·17; 95% CI 0·16–0·19, p<0·001). Sore throat was more common during omicron prevalence than during delta prevalence (70·5% vs 60·8%, 1·55; 1·43–1·69, p<0·001). There was a lower rate of hospital admission during omicron prevalence than during delta prevalence (1·9% vs 2·6%, OR 0·75; 95% CI 0·57–0·98, p=0·03). The prevalence of symptoms that characterise an omicron infection differs from those of the delta SARS-CoV-2 variant, apparently with less involvement of the lower respiratory tract and reduced probability of hospital admission. Our data indicate a shorter period of illness and potentially of infectiousness which should impact work–health policies and public health advice. Wellcome Trust, ZOE, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, and Medical Research Council [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=157139852 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S0140-6736(22)00327-0 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 7 StartPage: 1618 Titles: – TitleFull: Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Menni, Cristina – PersonEntity: Name: NameFull: Valdes, Ana M – PersonEntity: Name: NameFull: Polidori, Lorenzo – PersonEntity: Name: NameFull: Antonelli, Michela – PersonEntity: Name: NameFull: Penamakuri, Satya – PersonEntity: Name: NameFull: Nogal, Ana – PersonEntity: Name: NameFull: Louca, Panayiotis – PersonEntity: Name: NameFull: May, Anna – PersonEntity: Name: NameFull: Figueiredo, Jane C – PersonEntity: Name: NameFull: Hu, Christina – PersonEntity: Name: NameFull: Molteni, Erika – PersonEntity: Name: NameFull: Canas, Liane – PersonEntity: Name: NameFull: Österdahl, Marc F – PersonEntity: Name: NameFull: Modat, Marc – PersonEntity: Name: NameFull: Sudre, Carole H – PersonEntity: Name: NameFull: Fox, Ben – PersonEntity: Name: NameFull: Hammers, Alexander – PersonEntity: Name: NameFull: Wolf, Jonathan – PersonEntity: Name: NameFull: Capdevila, Joan – PersonEntity: Name: NameFull: Chan, Andrew T IsPartOfRelationships: – BibEntity: Dates: – D: 23 M: 04 Text: 4/23/2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 01406736 Numbering: – Type: volume Value: 399 – Type: issue Value: 10335 Titles: – TitleFull: Lancet Type: main |
| ResultId | 1 |
